InvestorsHub Logo
Followers 288
Posts 22878
Boards Moderated 1
Alias Born 01/30/2007

Re: None

Friday, 08/22/2014 12:12:10 PM

Friday, August 22, 2014 12:12:10 PM

Post# of 3898
The Company is currently enrolling patients for its fifth dose group (225 mg), and the MTD has not yet been achieved. Depending upon the number of dose groups needed to determine the MTD, Rexahn expects to complete this trial in the fourth quarter of 2014.